Dostarlimab Plus Chemotherapy Meets ORR End Point in Metastatic Nonsquamous NSCLC
The addition of dostarlimab to chemotherapy led to an improvement in objective response rate versus pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non‑small cell lung cancer.
The addition of dostarlimab to chemotherapy led to an improvement in objective response rate versus pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non‑small cell lung cancer.
This shows the potential of dostarlimab, a PD‑1 inhibitor, to improve response rates over existing standard-of-care therapy in a difficult-to‑treat subset of lung cancer patients (metastatic nonsquamous NSCLC).
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT